The Emphysema Treatment Market valued for $4,474.71 million in 2021 and is estimated to reach $7,292.90 million by 2031, exhibiting a CAGR of 5% from 2022 to 2031.
Emphysema and chronic bronchitis are the most common conditions that make up chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease is a group of lung diseases that block airflow and make it difficult to breathe. Abnormalities in the small airways of the lungs lead to limitation of airflow in and out of the lungs. Several processes cause the airways to become narrow. There may be destruction of parts of the lung, mucus blocking the airways, and inflammation & swelling of the airway lining. COPD is sometimes called emphysema or chronic bronchitis. Emphysema usually refers to destruction of the tiny air sacs at the end of the airways in the lungs. There is no cure for COPD, however early diagnosis and treatment are important to slow the progression of symptoms and reduce the risk of flare-ups.
The driving factors for emphysema treatment market are increase in prevalence of emphysema across the world owing to rise in number of smokers in many regions. For instance, according to article published in National Library of Medicine, 2022, prevalence of emphysema in U.S., is approximately 14 million and is leading COPD disorder across the country. In addition, to eliminate the occurrence and progression of condition associated with chronic obstructive pulmonary disease (COPD), early diagnosis and treatment is essential, which contributes to growth of emphysema treatment market. For instance, according to an article published in National Library of Medicine 2022, prevalence of chronic obstructive pulmonary disease (COPD) is increasing in North India accounting for 19.4% and Bangladesh with 13.5%. Further, surge in number of smokers across the globe results in increase in prevalence of emphysema, thereby driving the market growth. For instance, according to World Health Organization (WHO) 2021, 22.3% world’s population used tobacco with 1.3 million tobacco smokers residing in low and middle-income countries. Thus, increase in prevalence of emphysema cases, rise in number of smokers, awareness regarding emphysema, and treatment drive the growth of emphysema treatment market during forecast period.
However, side effects of the drug used in emphysema treatment restrain the growth of emphysema treatment market. In addition, failure of new drugs in clinical trials, also might hinder the growth of market.
The global emphysema treatment market is segmented into medication type, distribution channel, and region. On the basis of medication type, the market is segregated into bronchodilators, steroids, and others. On the basis of distribution channel, the market is categorized into hospitals pharmacies, online providers, and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global Emphysema treatment market are AstraZeneca, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline Plc., Mylan Pharmaceuticals (Viatris), Teva Pharmaceuticals, Hikma Pharmaceuticals Plc, Orion Corporation, Pfizer, Inc., and Verona pharma.
Emphysema and chronic bronchitis are the most common conditions that make up chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease is a group of lung diseases that block airflow and make it difficult to breathe. Abnormalities in the small airways of the lungs lead to limitation of airflow in and out of the lungs. Several processes cause the airways to become narrow. There may be destruction of parts of the lung, mucus blocking the airways, and inflammation & swelling of the airway lining. COPD is sometimes called emphysema or chronic bronchitis. Emphysema usually refers to destruction of the tiny air sacs at the end of the airways in the lungs. There is no cure for COPD, however early diagnosis and treatment are important to slow the progression of symptoms and reduce the risk of flare-ups.
The driving factors for emphysema treatment market are increase in prevalence of emphysema across the world owing to rise in number of smokers in many regions. For instance, according to article published in National Library of Medicine, 2022, prevalence of emphysema in U.S., is approximately 14 million and is leading COPD disorder across the country. In addition, to eliminate the occurrence and progression of condition associated with chronic obstructive pulmonary disease (COPD), early diagnosis and treatment is essential, which contributes to growth of emphysema treatment market. For instance, according to an article published in National Library of Medicine 2022, prevalence of chronic obstructive pulmonary disease (COPD) is increasing in North India accounting for 19.4% and Bangladesh with 13.5%. Further, surge in number of smokers across the globe results in increase in prevalence of emphysema, thereby driving the market growth. For instance, according to World Health Organization (WHO) 2021, 22.3% world’s population used tobacco with 1.3 million tobacco smokers residing in low and middle-income countries. Thus, increase in prevalence of emphysema cases, rise in number of smokers, awareness regarding emphysema, and treatment drive the growth of emphysema treatment market during forecast period.
However, side effects of the drug used in emphysema treatment restrain the growth of emphysema treatment market. In addition, failure of new drugs in clinical trials, also might hinder the growth of market.
The global emphysema treatment market is segmented into medication type, distribution channel, and region. On the basis of medication type, the market is segregated into bronchodilators, steroids, and others. On the basis of distribution channel, the market is categorized into hospitals pharmacies, online providers, and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global Emphysema treatment market are AstraZeneca, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline Plc., Mylan Pharmaceuticals (Viatris), Teva Pharmaceuticals, Hikma Pharmaceuticals Plc, Orion Corporation, Pfizer, Inc., and Verona pharma.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the emphysema treatment market analysis from 2021 to 2031 to identify the prevailing emphysema treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the emphysema treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global emphysema treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Medication Type
- Bronchodilators
- Steroids
- Others
By Distribution Channel
- Online Providers
- Drug Stores and Retail Pharmacies
- Hospital Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Pfizer, Inc.
- teva pharmaceuticals
- orion corporation
- GlaxoSmithKline plc
- Hikma Pharmaceuticals plc
- Verona Pharma
- Novartis AG
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Mylan Pharmaceuticals ( a subsidiary of Viatris)
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Moderate threat of substitutes
3.3.4. Moderate threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of emphysema cases
3.4.1.2. Increase in number of smokers leading to emphysema
3.4.1.3. Increase in air pollution and genetic risk factor contributing to emphysema
3.4.2. Restraints
3.4.2.1. Side effects associated with medications
3.4.2.2. High cost of treatment
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: EMPHYSEMA TREATMENT MARKET, BY MEDICATION TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Bronchodilators
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Steroids
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: EMPHYSEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital Pharmacies
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Online Providers
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Drug Stores and Retail Pharmacies
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: EMPHYSEMA TREATMENT MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. Market size and forecast, by Medication Type
6.2.3. Market size and forecast, by Distribution Channel
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Key market trends, growth factors and opportunities
6.2.4.1.2. Market size and forecast, by Medication Type
6.2.4.1.3. Market size and forecast, by Distribution Channel
6.2.4.2. Canada
6.2.4.2.1. Key market trends, growth factors and opportunities
6.2.4.2.2. Market size and forecast, by Medication Type
6.2.4.2.3. Market size and forecast, by Distribution Channel
6.2.4.3. Mexico
6.2.4.3.1. Key market trends, growth factors and opportunities
6.2.4.3.2. Market size and forecast, by Medication Type
6.2.4.3.3. Market size and forecast, by Distribution Channel
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Market size and forecast, by Medication Type
6.3.3. Market size and forecast, by Distribution Channel
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Key market trends, growth factors and opportunities
6.3.4.1.2. Market size and forecast, by Medication Type
6.3.4.1.3. Market size and forecast, by Distribution Channel
6.3.4.2. France
6.3.4.2.1. Key market trends, growth factors and opportunities
6.3.4.2.2. Market size and forecast, by Medication Type
6.3.4.2.3. Market size and forecast, by Distribution Channel
6.3.4.3. UK
6.3.4.3.1. Key market trends, growth factors and opportunities
6.3.4.3.2. Market size and forecast, by Medication Type
6.3.4.3.3. Market size and forecast, by Distribution Channel
6.3.4.4. Italy
6.3.4.4.1. Key market trends, growth factors and opportunities
6.3.4.4.2. Market size and forecast, by Medication Type
6.3.4.4.3. Market size and forecast, by Distribution Channel
6.3.4.5. Spain
6.3.4.5.1. Key market trends, growth factors and opportunities
6.3.4.5.2. Market size and forecast, by Medication Type
6.3.4.5.3. Market size and forecast, by Distribution Channel
6.3.4.6. Rest of Europe
6.3.4.6.1. Key market trends, growth factors and opportunities
6.3.4.6.2. Market size and forecast, by Medication Type
6.3.4.6.3. Market size and forecast, by Distribution Channel
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Market size and forecast, by Medication Type
6.4.3. Market size and forecast, by Distribution Channel
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Key market trends, growth factors and opportunities
6.4.4.1.2. Market size and forecast, by Medication Type
6.4.4.1.3. Market size and forecast, by Distribution Channel
6.4.4.2. China
6.4.4.2.1. Key market trends, growth factors and opportunities
6.4.4.2.2. Market size and forecast, by Medication Type
6.4.4.2.3. Market size and forecast, by Distribution Channel
6.4.4.3. Australia
6.4.4.3.1. Key market trends, growth factors and opportunities
6.4.4.3.2. Market size and forecast, by Medication Type
6.4.4.3.3. Market size and forecast, by Distribution Channel
6.4.4.4. India
6.4.4.4.1. Key market trends, growth factors and opportunities
6.4.4.4.2. Market size and forecast, by Medication Type
6.4.4.4.3. Market size and forecast, by Distribution Channel
6.4.4.5. South Korea
6.4.4.5.1. Key market trends, growth factors and opportunities
6.4.4.5.2. Market size and forecast, by Medication Type
6.4.4.5.3. Market size and forecast, by Distribution Channel
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Key market trends, growth factors and opportunities
6.4.4.6.2. Market size and forecast, by Medication Type
6.4.4.6.3. Market size and forecast, by Distribution Channel
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. Market size and forecast, by Medication Type
6.5.3. Market size and forecast, by Distribution Channel
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Key market trends, growth factors and opportunities
6.5.4.1.2. Market size and forecast, by Medication Type
6.5.4.1.3. Market size and forecast, by Distribution Channel
6.5.4.2. Saudi Arabia
6.5.4.2.1. Key market trends, growth factors and opportunities
6.5.4.2.2. Market size and forecast, by Medication Type
6.5.4.2.3. Market size and forecast, by Distribution Channel
6.5.4.3. South Africa
6.5.4.3.1. Key market trends, growth factors and opportunities
6.5.4.3.2. Market size and forecast, by Medication Type
6.5.4.3.3. Market size and forecast, by Distribution Channel
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Key market trends, growth factors and opportunities
6.5.4.4.2. Market size and forecast, by Medication Type
6.5.4.4.3. Market size and forecast, by Distribution Channel
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2021
CHAPTER 8: COMPANY PROFILES
8.1. Novartis AG
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.2. Mylan Pharmaceuticals ( a subsidiary of Viatris)
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.3. teva pharmaceuticals
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Verona Pharma
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.5. Hikma Pharmaceuticals plc
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. orion corporation
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Pfizer, Inc.
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.8. GlaxoSmithKline plc
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Boehringer Ingelheim International GmbH
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. AstraZeneca
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
List of Tables
Table 01. Global Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 02. Emphysema Treatment Market for Bronchodilators, by Region, 2021-2031 (Revenue, $Million)
Table 03. Emphysema Treatment Market for Steroids, by Region, 2021-2031 (Revenue, $Million)
Table 04. Emphysema Treatment Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 05. Global Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 06. Emphysema Treatment Market for Hospital Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 07. Emphysema Treatment Market for Online Providers, by Region, 2021-2031 (Revenue, $Million)
Table 08. Emphysema Treatment Market for Drug Stores and Retail Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 09. Emphysema Treatment Market, by Region, 2021-2031 (Revenue, $Million)
Table 10. North America Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 11. North America Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 12. North America Emphysema Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 13. U.S. Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 14. U.S. Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 15. Canada Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 16. Canada Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 17. Mexico Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 18. Mexico Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 19. Europe Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 20. Europe Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 21. Europe Emphysema Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 22. Germany Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 23. Germany Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 24. France Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 25. France Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 26. UK Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 27. UK Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 28. Italy Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 29. Italy Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 30. Spain Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 31. Spain Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 32. Rest of Europe Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 33. Rest of Europe Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 34. Asia-Pacific Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 35. Asia-Pacific Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 36. Asia-Pacific Emphysema Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 37. Japan Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 38. Japan Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 39. China Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 40. China Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 41. Australia Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 42. Australia Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 43. India Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 44. India Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 45. South Korea Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 46. South Korea Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 47. Rest of Asia-Pacific Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 48. Rest of Asia-Pacific Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 49. LAMEA Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 50. LAMEA Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 51. LAMEA Emphysema Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 52. Brazil Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 53. Brazil Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 54. Saudi Arabia Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 55. Saudi Arabia Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 56. South Africa Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 57. South Africa Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 58. Rest of LAMEA Emphysema Treatment Market, by Medication Type, 2021-2031 (Revenue, $Million)
Table 59. Rest of LAMEA Emphysema Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 60. Novartis Ag: Key Executives
Table 61. Novartis Ag: Company Snapshot
Table 62. Novartis Ag: Product Segments
Table 63. Novartis Ag: Product Portfolio
Table 64. Mylan Pharmaceuticals ( a Subsidiary of Viatris): Key Executives
Table 65. Mylan Pharmaceuticals ( a Subsidiary of Viatris): Company Snapshot
Table 66. Mylan Pharmaceuticals ( a Subsidiary of Viatris): Product Segments
Table 67. Mylan Pharmaceuticals ( a Subsidiary of Viatris): Product Portfolio
Table 68. Teva Pharmaceuticals: Key Executives
Table 69. Teva Pharmaceuticals: Company Snapshot
Table 70. Teva Pharmaceuticals: Product Segments
Table 71. Teva Pharmaceuticals: Product Portfolio
Table 72. Teva Pharmaceuticals: Key Stratergies
Table 73. Verona Pharma: Key Executives
Table 74. Verona Pharma: Company Snapshot
Table 75. Verona Pharma: Product Segments
Table 76. Verona Pharma: Product Portfolio
Table 77. Hikma Pharmaceuticals plc: Key Executives
Table 78. Hikma Pharmaceuticals plc: Company Snapshot
Table 79. Hikma Pharmaceuticals plc: Product Segments
Table 80. Hikma Pharmaceuticals plc: Product Portfolio
Table 81. Hikma Pharmaceuticals plc: Key Stratergies
Table 82. Orion Corporation: Key Executives
Table 83. Orion Corporation: Company Snapshot
Table 84. Orion Corporation: Product Segments
Table 85. Orion Corporation: Product Portfolio
Table 86. Orion Corporation: Key Stratergies
Table 87. Pfizer, Inc.: Key Executives
Table 88. Pfizer, Inc.: Company Snapshot
Table 89. Pfizer, Inc.: Product Segments
Table 90. Pfizer, Inc.: Product Portfolio
Table 91. GlaxoSmithKline plc: Key Executives
Table 92. GlaxoSmithKline plc: Company Snapshot
Table 93. GlaxoSmithKline plc: Product Segments
Table 94. GlaxoSmithKline plc: Product Portfolio
Table 95. GlaxoSmithKline plc: Key Stratergies
Table 96. Boehringer Ingelheim International Gmbh: Key Executives
Table 97. Boehringer Ingelheim International Gmbh: Company Snapshot
Table 98. Boehringer Ingelheim International Gmbh: Product Segments
Table 99. Boehringer Ingelheim International Gmbh: Product Portfolio
Table 100. Boehringer Ingelheim International Gmbh: Key Stratergies
Table 101. Astrazeneca: Key Executives
Table 102. Astrazeneca: Company Snapshot
Table 103. Astrazeneca: Product Segments
Table 104. Astrazeneca: Product Portfolio
Table 105. Astrazeneca: Key Stratergies
List of Figures
Figure 01. Emphysema Treatment Market, 2021-2031
Figure 02. Segmentation of Emphysema Treatment Market, 2021-2031
Figure 03. Top Investment Pockets in Emphysema Treatment Market (2022-2031)
Figure 04. Moderate Bargaining Power of Suppliers
Figure 05. Moderate Bargaining Power of Buyers
Figure 06. Moderate Threat of Substitutes
Figure 07. Moderate Threat of New Entrants
Figure 08. Moderate Intensity of Rivalry
Figure 09. Drivers, Restraints and Opportunities: Globalemphysema Treatment Market
Figure 10. Emphysema Treatment Market, by Medication Type, 2021 (%)
Figure 11. Comparative Share Analysis of Emphysema Treatment Market for Bronchodilators, by Country 2021-2031 (%)
Figure 12. Comparative Share Analysis of Emphysema Treatment Market for Steroids, by Country 2021-2031 (%)
Figure 13. Comparative Share Analysis of Emphysema Treatment Market for Others, by Country 2021-2031 (%)
Figure 14. Emphysema Treatment Market, by Distribution Channel, 2021 (%)
Figure 15. Comparative Share Analysis of Emphysema Treatment Market for Hospital Pharmacies, by Country 2021-2031 (%)
Figure 16. Comparative Share Analysis of Emphysema Treatment Market for Online Providers, by Country 2021-2031 (%)
Figure 17. Comparative Share Analysis of Emphysema Treatment Market for Drug Stores and Retail Pharmacies, by Country 2021-2031 (%)
Figure 18. Emphysema Treatment Market by Region, 2021
Figure 19. U.S. Emphysema Treatment Market, 2021-2031 ($Million)
Figure 20. Canada Emphysema Treatment Market, 2021-2031 ($Million)
Figure 21. Mexico Emphysema Treatment Market, 2021-2031 ($Million)
Figure 22. Germany Emphysema Treatment Market, 2021-2031 ($Million)
Figure 23. France Emphysema Treatment Market, 2021-2031 ($Million)
Figure 24. UK Emphysema Treatment Market, 2021-2031 ($Million)
Figure 25. Italy Emphysema Treatment Market, 2021-2031 ($Million)
Figure 26. Spain Emphysema Treatment Market, 2021-2031 ($Million)
Figure 27. Rest of Europe Emphysema Treatment Market, 2021-2031 ($Million)
Figure 28. Japan Emphysema Treatment Market, 2021-2031 ($Million)
Figure 29. China Emphysema Treatment Market, 2021-2031 ($Million)
Figure 30. Australia Emphysema Treatment Market, 2021-2031 ($Million)
Figure 31. India Emphysema Treatment Market, 2021-2031 ($Million)
Figure 32. South Korea Emphysema Treatment Market, 2021-2031 ($Million)
Figure 33. Rest of Asia-Pacific Emphysema Treatment Market, 2021-2031 ($Million)
Figure 34. Brazil Emphysema Treatment Market, 2021-2031 ($Million)
Figure 35. Saudi Arabia Emphysema Treatment Market, 2021-2031 ($Million)
Figure 36. South Africa Emphysema Treatment Market, 2021-2031 ($Million)
Figure 37. Rest of LAMEA Emphysema Treatment Market, 2021-2031 ($Million)
Figure 38. Top Winning Strategies, by Year
Figure 39. Top Winning Strategies, by Development
Figure 40. Top Winning Strategies, by Company
Figure 41. Product Mapping of Top 10 Players
Figure 42. Competitive Dashboard
Figure 43. Competitive Heatmap: Emphysema Treatment Market
Figure 44. Top Player Positioning, 2021
Figure 45. Novartis Ag: Net Sales, 2019-2021 ($Million)
Figure 46. Novartis Ag: Revenue Share by Segment, 2021 (%)
Figure 47. Novartis Ag: Revenue Share by Region, 2021 (%)
Figure 48. Mylan Pharmaceuticals ( a Subsidiary of Viatris): Net Sales, 2020-2021 ($Million)
Figure 49. Mylan Pharmaceuticals ( a Subsidiary of Viatris): Revenue Share by Segment, 2021 (%)
Figure 50. Mylan Pharmaceuticals ( a Subsidiary of Viatris): Revenue Share by Region, 2021 (%)
Figure 51. Teva Pharmaceuticals: Net Revenue, 2019-2021 ($Million)
Figure 52. Teva Pharmaceuticals: Revenue Share by Region, 2021 (%)
Figure 53. Verona Pharma: Net Sales, 2019-2021 ($Million)
Figure 54. Hikma Pharmaceuticals plc: Net Revenue, 2019-2021 ($Million)
Figure 55. Hikma Pharmaceuticals plc: Revenue Share by Segment, 2021 (%)
Figure 56. Hikma Pharmaceuticals plc: Revenue Share by Region, 2021 (%)
Figure 57. Orion Corporation: Net Sales, 2019-2021 ($Million)
Figure 58. Orion Corporation: Revenue Share by Segment, 2021 (%)
Figure 59. Pfizer, Inc.: Net Revenue, 2019-2021 ($Million)
Figure 60. Pfizer, Inc.: Revenue Share by Region, 2021 (%)
Figure 61. GlaxoSmithKline plc: Net Sales, 2019-2021 ($Million)
Figure 62. GlaxoSmithKline plc: Revenue Share by Segment, 2021 (%)
Figure 63. GlaxoSmithKline plc: Revenue Share by Region, 2021 (%)
Figure 64. Boehringer Ingelheim International Gmbh: Net Sales, 2019-2021 ($Million)
Figure 65. Boehringer Ingelheim International Gmbh: Revenue Share by Segment, 2021 (%)
Figure 66. Boehringer Ingelheim International Gmbh: Revenue Share by Region, 2021 (%)
Figure 67. Astrazeneca: Net Sales, 2019-2021 ($Million)
Figure 68. Astrazeneca: Revenue Share by Region, 2021 (%)
Executive Summary
According to the report titled, “Emphysema Treatment Market," The emphysema treatment market was valued at $4,474.71 million in 2021 and is estimated to reach $7,292.90 million by 2031, growing at a CAGR of 5% from 2022 to 2031.Emphysema, a lung disease is characterized by the shortness of breath, thereby, damaging the air sacs in the lungs. In these condition lungs tiny air sac called as alveoli stretch out of shape and ruptured as a result these rupture alveoli become destroyed, damaged and lose their elasticity. Over time, the inner lining of the alveoli becomes weak and causes air to stay trapped inside the lungs because the damaged lung sacs can't empty. It is a progressive condition and worsens over time, due to this lung lose their ability to absorb oxygen and release carbon dioxide, and breathing becomes difficult.
Key factors driving the growth of the emphysema treatment market include rise in prevalence of emphysema cases, expeditious innovation of novel dosage forms and new formulations of existing drugs. In many regions, rise in prevalence of emphysema cases is seen because of alpha-1 antitrypsin deficiency which leads to rise in demand of novel therapies and medications. For instance, according to article published in National Library of Medicine 2019, stated that, approximately 2% to 3% of patients diagnosed with COPD have alpha-1 antitrypsin deficiency (AATD), and severe AATD has been reported in 1% to 2% of patients in the U.S. Further, many new combinations of medications in single inhaler for treating emphysema are being approved which fuels the growth of this market. For instance, in 2019, AstraZeneca announced that budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Furthermore, awareness regarding chronic obstructive pulmonary disease (COPD) and treatment management across the globe fuels the growth of emphysema treatment market. In addition, many key players have adopted key strategies such as partnership, collaboration and merger for effective formulation of effective drugs for treatment of emphysema. For instance, in December 2019, Highmark and Boehringer Ingelheim announced a new value-based contract for Boehringer Ingelheim's StioltoR. RespimatR. (tiotropium bromide and olodaterol) inhalation spray for the treatment of chronic obstructive pulmonary disease (COPD).
Further, rise in number of smokers is expected to drive the market growth, as cigarette blocks air flow passage leading to difficulty in breathing. For instance, according to report published by American Lung Association 2022, 80% of emphysema cases are associated with chemicals, which are released through cigarette, thus rise in number of smokers results in number of emphysema cases, driving the market growth. In addition, burning of biomass fuel can generate huge amounts of pollutants such as particulate matter, carbon monoxide, nitrogen oxides (NOx), benzene, and polycyclic aromatic hydrocarbons leading to emphysema. For instance, according to the article published in National Institute of Health 2019, difference in ozone levels of 3 parts per billion over a decade was associated with an increase in emphysema equivalent to smoking a pack of cigarettes a day for almost 30 years.
The market also offers growth opportunities to the key players in the market. Many developing regions such India and UK offer lucrative opportunities to key players of emphysema treatment market owing to high population base, increase in demand of novel medications for emphysema and increase in healthcare spending. In addition, government sponsored research studies for chronic obstructive pulmonary disease (COPD) in various countries and medical tourism fuels the growth of market.
The global emphysema treatment market is segmented into medication type, distribution channel and region. On the basis of medication type, the market is segregated into bronchodilators, steroids and others. On the basis of distribution channel, the market is categorized into hospitals pharmacies, online providers, and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major Key players that operate in the global thalassemia market are AstraZeneca, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline Plc., Mylan Pharmaceuticals (Viatris), Teva Pharmaceuticals, Hikma Pharmaceuticals Plc, Orion Corporation, Pfizer, Inc. and Verona pharma. The players in the market have been actively engaged in the adoption various strategies such as acquisition, product launch and product approval to remain competitive and gain advantage over the competitors in the market. For instance, in July 2021, Teva Pharmaceutical Industries Ltd., launched first generic version of twice daily PERFOROMIST, formoterol fumarate inhalation solution, 20 mcg/2 mL, indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Key Market Insights
- By medication type, the bronchodilators segment was highest revenue contributor to the market & is anticipated to grow at highest CAGR of 6.3%.
- On the basis of distribution channel, the drug stores & retail pharmacies segment dominated the market in 2021. However, online providers are anticipated to grow at the highest CAGR of 6.4% during the forecast period.
- Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Pfizer, Inc.
- teva pharmaceuticals
- orion corporation
- GlaxoSmithKline plc
- Hikma Pharmaceuticals plc
- Verona Pharma
- Novartis AG
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Mylan Pharmaceuticals ( a subsidiary of Viatris)
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
